A southwest oncology group and cancer-and leukemia group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma

Cancer

Volumn 82, Issue 7, 1998, Pages 1288-1295

  Antman, Karen ^a   Crowley, John ^b   Balcerzak, Stanley P ^c   Kempt, Raymond A ^d   Weiss, Raymond B ^e   Clamon, Gerald H ^f   Baker, Laurence H ^g  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

^b SW Oncology Group Statistical Center ^*  (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e WALTER REED ARMY MEDICAL CENTER   (United States)

^f UNIVERSITY OF IOWA   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Adult; Ewing's sarcoma; Osteosarcoma; Rhabdomyosarcoma

Indexed keywords

CISPLATIN; DACARBAZINE; DOXORUBICIN; IFOSFAMIDE; MESNA;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; EWING SARCOMA; FEMALE; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOSARCOMA; SOMNOLENCE; THROMBOCYTOPENIA;

EID: 0032055170     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980401)82:7<1288::AID-CNCR11>3.0.CO;2-2     Document Type: Article

References (24)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
2. Eilber F, Guiliano A, Eckardt J, Patterson K, Moseley S, Goodnight J. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 1987;5:21-6.
3. Link M, Goorin A, Miser A, Green A, Pratt C, Belasco J, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986;314:1600-6.
4. Miser JS, Kinsella TJ, Triche TJ, Tsokos M, Jarosinski P, Forquer R, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 1987;5:1191-8.
5. Demeocq F, Oberlin O, Benz-Lemoine E, Boilletot A, Gentet JC, Zucker JM, et al. Initial chemotherapy including ifosfamide in the management of Ewing's sarcoma: preliminary results. A protocol of the French Pediatric Oncology Society. Cancer Chemother Pharmacol 1989;24:S45-7.
6. Otten J, Flamant F, Rodary C, Brunat-Mentigny M, Dutou L, Quintana E, et al. Effectiveness of combination of ifosfamide, vincristine and actinomycin D in inducing remission in rhabdomyosarcoma in children. For the RMS group of the International Society of Pediatric Oncology. Proc Am Soc Clin Oncol 1985;4:236.
7. Siegel RD, Ryan LM, Antman KH. Adults with Ewing's sarcoma: an analysis of 16 patients at the Dana-Farber Cancer Institute. Am J Clin Oncol 1988;11:614-7.
8. Siegel RD, Corson JM, Ryan LM, Antman KH. Osteosarcoma in adults. Clin Orthop 1989;240:261-9.
9. Ang PT, Molina A, Torti FM, Jacobs CD. Rhabdomyosarcoma in adults: combined modality therapy [abstract 1197]. Proc Am Soc Clin Oncol 1990;9:309.
10. Omura GA, Major FJ, Blessing JA, Sedlacek TV, Thigpen IT, Creasman WT, et al. A randomized study of Adriamycin with and without dimethyl trazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 1983;52:626-32.
11. Lerner H, Amato D, Stevens C, Borden E, Enterline H. Leiomyosarcoma: the Eastern Cooperative Oncology Group experience with 222 patients [abstract C-561]. Proc Am Assoc Cancer Res 1983;24:142.
12. Borden EC, Amato D, Enterline HT, Lerner H, Carrbone PP. Randomized comparison of Adriamycin regimens for treatment of metastatic soft tissue sarcomas. J Clin Oncol 1987; 5:840-50.
13. Benjamin RS, Gottlieb JA, Baker LH. CYVADIC vs CYVADACT-A randomized trial of cyclophosphamide, vincristine and Adriamycin, plus either dacarbazine or actinomycin D in metastatic sarcomas. Proc Am Assoc Cancer Res 1976;17: 256.
14. Antman K, Crowley J, Balcerzak SP, Rivkin S, Weiss G, Elias A, et al. An Intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced tissue and bone sarcomas. J Clin Oncol 1993;11: 1276-85.
15. Edmonson JH, Ryan L, Blum RH, Brooks JSJ, Shiroki M, Frytak S, et al. Randomized comparison of of doxorubicin alone vs ifosphamide and doxorubicin or mitomycin, doxorubicin, cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993;11:1269-75.
16. Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first line treatment of advanced soft tissue sarcomas: a study of the EORTC. J Clin Oncol 1995;13: 1537-45.
17. Cox DR. Analysis of binary data. London: Chapman and Hall, 1970.
18. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother 1966;50:163-70.
19. Cox DR. Regression models and life tables. J Roy Stat Soc S [B] 1972;34:187-202.
20. Kaplan EL, Meier R. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
21. Enzinger FM, Weiss SW. Soft tissue tumors. St Louis: C.V. Mosby, 1988.
22. Fraumeni JF Jr, Boice JD Jr. Bone. Schottenfeld D, editor. Cancer/Epidemiology. Philadelphia: W.B. Saunders, 1987: 814-26.
23. Dahlin D. Bone tumors: general aspects and data on 6,221 cases. 3rd edition. Springfield, IL: Charles E. Tomas, Inc., 1978.
24. Russo P. Urologic sarcoma in adults. Urolo Clin North Am 1991;18:581-8.